Table 2 Univariate and multivariate analyses of OS in patients

Age (years)

≤60/> 60

1.718

0.880–3.356

0.113

NI

1.443

0.734–2.837

0.288

NI

Gender

Female / Male

1.537

0.764–3.093

0.228

NI

1.930

0.953–3.908

0.068

NI

Tumor size (cm)

≤2/2~4/>4

1.158

0.636–2.108

0.631

NI

1.404

0.763–2.584

0.275

NI

Tumor grade

Well / Moderate / Poor

1.030

0.597–1.778

0.915

NI

1.188

0.681–2.072

0.545

NI

LN metastasis

Absent / Present

0.677

0.332–1.379

0.282

NI

0.787

0.386–1.604

0.509

NI

Tumor site

Head / Body / Tail

0.942

0.575–1.544

0.814

NI

1.003

0.598–1.681

0.992

NI

WBC (*10⁹)

≤10/> 10

1.008

0.354–2.872

0.988

NI

0.878

0.305–2.525

0.809

NI

HGB (g/L)

≤120/> 120

0.656

0.254–1.693

0.383

NI

0.445

0.169–1.174

0.102

NI

PLT (*10⁹)

≤300/> 300

1.220

0.503–2.957

0.660

NI

1.521

0.614–3.764

0.365

NI

ALT (U/L)

≤40/>40

0.768

0.348–1.696

0.514

NI

0.790

0.356–1.752

0.562

NI

AST (U/L)

≤40/>40

0.497

0.175–1.410

0.189

NI

0.540

0.190–1.537

0.248

NI

ALP (U/L)

≤100/>100

0.919

0.456–1.854

0.813

NI

0.905

0.446–1.840

0.784

NI

GGT (U/L)

≤45/>45

0.898

0.459–1.760

0.755

NI

0.989

0.501–1.950

0.974

NI

ALB (g/L)

≤40/> 40

0.317

0.117–0.857

0.024

0.363

0.130–1.012

0.053

0.346

0.128–0.934

0.036

0.389

0.141–1.076

0.069

TBIL (umol/L)

≤20.5/>20.5

0.649

0.251–1.675

0.371

NI

0.715

0.275–1.855

0.490

NI

IBIL (umol/L)

≤15/>15

0.483

0.066–3.557

0.475

NI

0.437

0.059–3.215

0.416

NI

CRP (ng/L)

≤3/>3

4.040

1.974–8.266

<0.001

3.567

1.741–7.309

0.001

3.939

1.867–8.311

<0.001

3.432

1.628–7.238

0.001

CEA (ng/mL)

≤5/>5

1.372

0.687–2.741

0.370

NI

1.414

0.702–2.850

0.333

NI

CA19–9 (U/ml)

≤35/>35

1.650

0.720–3.782

0.237

NI

2.056

0.848–4.987

0.111

NI

Chemotherapy

With IRE/ With radiotherapy

0.424

0.183–0.892

0.045

0.422

0.177–0.998

0.049

0.355

0.154–0.822

0.016

0.362

0.153–0.854

0.020

Cheotherapy type

FOLFIRINOX/Gem

0.834

0.596–1.168

0.291

NI

0.864

0.613–1.219

0.407

NI